# SOCS6

## Overview
Suppressor of Cytokine Signaling 6 (SOCS6) is a gene that encodes a protein belonging to the SOCS family, which plays a critical role in the negative regulation of cytokine signaling pathways. The SOCS6 protein is characterized as an adaptor protein, featuring a central SH2 domain and a C-terminal SOCS box, which are essential for its function in targeting proteins for ubiquitin-mediated degradation (Linossi2018Understanding; Kabir2014SOCS6). This protein is involved in the regulation of receptor tyrosine kinase signaling, particularly through interactions with the KIT receptor, and plays a significant role in maintaining cellular homeostasis by preventing excessive signaling that could lead to pathological conditions such as cancer (Bayle2004Suppressor). Additionally, SOCS6 is implicated in mitochondrial dynamics, where it promotes mitochondrial fission, contributing to its proapoptotic functions (Lin2012Suppressor). The gene's expression and function are often altered in various cancers, highlighting its potential as a biomarker for cancer prognosis and as a target for therapeutic interventions (Ouyang2021Downregulation; Kabir2014SOCS6).

## Structure
SOCS6 is a member of the suppressor of cytokine signaling family, characterized by its distinct structural domains. The protein contains an extended N-terminal region, a central SH2 domain, and a C-terminal SOCS box. The SH2 domain is crucial for binding to phosphotyrosine residues on target proteins, facilitating interactions necessary for its regulatory functions (Linossi2018Understanding; Kabir2014SOCS6). The SOCS box is involved in recruiting the ubiquitin ligase machinery, directing proteins towards ubiquitin-mediated degradation (Lin2012Suppressor; Kabir2014SOCS6). This domain is essential for SOCS6's mitochondrial localization and function, as it mediates interactions with other adaptor proteins in the Elongin BC-Cul2/Cul5-SOCS box protein (ECS) E3 ligase complexes (Lin2012Suppressor).

SOCS6 also features an extended SH2-subdomain (ESS), which contributes to its binding specificity and stability (Linossi2018Understanding). The N-terminal region of SOCS6 is longer and less characterized, containing several proline-rich motifs that suggest interactions with SH3 domain-containing proteins (Kabir2014SOCS6). SOCS6 is known to undergo post-translational modifications, such as phosphorylation, which may influence its function and interactions (Lin2012Suppressor). The protein can exist in multiple splice variant isoforms, potentially affecting its regulatory roles (Lin2012Suppressor).

## Function
Suppressor of Cytokine Signaling 6 (SOCS6) is a protein involved in the negative regulation of receptor tyrosine kinase signaling, primarily by promoting the degradation of receptors or substrate proteins through ubiquitination. This regulatory function helps maintain the balance of signaling pathways, preventing over-activation that could lead to disorders such as cancer (Kabir2014SOCS6). SOCS6 specifically interacts with the KIT receptor, where it binds to phosphorylated tyrosine residues, particularly Tyr-567, in the juxtamembrane domain. This interaction negatively regulates KIT receptor-mediated cell proliferation by down-regulating the activation of ERK1/2 and p38 MAPK pathways, while not affecting the AKT and STAT pathways (Bayle2004Suppressor).

SOCS6 also plays a role in mitochondrial dynamics, promoting mitochondrial fission by regulating the translocation of the dynamin-related protein 1 (DRP1) to mitochondria. This activity is crucial for maintaining mitochondrial morphology and is linked to SOCS6's proapoptotic function (Lin2012Suppressor). The protein's localization to mitochondria is essential for its function in mitochondrial fragmentation, and its loss can lead to increased antiapoptotic activity in cells (Lin2012Suppressor).

## Clinical Significance
SOCS6 is implicated in various cancers due to its role as a tumor suppressor. In gastrointestinal stromal tumors (GISTs), low SOCS6 expression is associated with larger tumor size and poorer overall survival and recurrence-free survival, making it an independent prognostic factor (Ouyang2021Downregulation). In lung squamous cell carcinoma (SCC), SOCS6 loss is linked to poor prognosis and increased tumor recurrence. This loss is characterized by reduced copy number and mRNA expression, which correlates with shorter overall survival (Sriram2012ArrayComparative). The gene's downregulation in lung cancer is often due to allelic loss and promoter hyper-methylation, contributing to poor survival outcomes (Kazi2014SOCS; Kabir2014SOCS6).

SOCS6 is also downregulated in colorectal cancer, with a significant reduction in expression observed across different stages of the disease (Letellier2014Identification). The gene's expression is frequently reduced in gastric, thyroid, and other cancers, often due to epigenetic modifications, suggesting its role in tumor suppression (Kabir2014SOCS6). These alterations in SOCS6 expression and function highlight its potential as a biomarker for cancer prognosis and therapy targets.

## Interactions
SOCS6 interacts with various proteins, playing a significant role in cellular signaling pathways. It is known to bind to the KIT receptor, specifically interacting with phosphorylated tyrosine residues Tyr-567 and Tyr-569 in the KIT juxtamembrane domain. This interaction is crucial for regulating KIT receptor signaling, as SOCS6 negatively influences pathways such as ERK1/2 and p38 MAPK, while not affecting AKT or STATs activation (Bayle2004Suppressor).

SOCS6 also interacts with the insulin receptor (INSR) and its substrates. It associates with INSR in response to insulin, inhibiting insulin-induced AKT and ERK1/2 phosphorylation, which suggests a role in counteracting insulin signaling (Kabir2014SOCS6). Additionally, SOCS6 binds to the regulatory subunit (p85) of PI3K upon insulin or IGF1 stimulation, leading to SOCS6 degradation rather than p85 degradation (Kabir2014SOCS6).

In mitochondrial dynamics, SOCS6 forms complexes with DRP1 and PGAM5, promoting DRP1 translocation to mitochondria and facilitating mitochondrial fission. This interaction is essential for SOCS6-induced mitochondrial fragmentation and apoptosis (Lin2012Suppressor). SOCS6's interaction with DRP1 is characterized by its ability to reduce DRP1 phosphorylation, enhancing its mitochondrial translocation (Lin2012Suppressor).


## References


[1. (Kazi2014SOCS) Julhash U. Kazi, Nuzhat N. Kabir, Amilcar Flores-Morales, and Lars Rönnstrand. Socs proteins in regulation of receptor tyrosine kinase signaling. Cellular and Molecular Life Sciences, 71(17):3297–3310, April 2014. URL: http://dx.doi.org/10.1007/s00018-014-1619-y, doi:10.1007/s00018-014-1619-y. This article has 79 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-014-1619-y)

[2. (Kabir2014SOCS6) Nuzhat N. Kabir, Jianmin Sun, Lars Rönnstrand, and Julhash U. Kazi. Socs6 is a selective suppressor of receptor tyrosine kinase signaling. Tumor Biology, 35(11):10581–10589, August 2014. URL: http://dx.doi.org/10.1007/s13277-014-2542-4, doi:10.1007/s13277-014-2542-4. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13277-014-2542-4)

[3. (Linossi2018Understanding) Edmond M. Linossi, Dale J. Calleja, and Sandra E. Nicholson. Understanding socs protein specificity. Growth Factors, 36(3–4):104–117, July 2018. URL: http://dx.doi.org/10.1080/08977194.2018.1518324, doi:10.1080/08977194.2018.1518324. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/08977194.2018.1518324)

[4. (Lin2012Suppressor) H-Y Lin, R-H Lai, S-T Lin, R-C Lin, M-J Wang, C-C Lin, H-C Lee, F-F Wang, and J-Y Chen. Suppressor of cytokine signaling 6 (socs6) promotes mitochondrial fission via regulating drp1 translocation. Cell Death &amp; Differentiation, 20(1):139–153, September 2012. URL: http://dx.doi.org/10.1038/cdd.2012.106, doi:10.1038/cdd.2012.106. This article has 59 citations.](https://doi.org/10.1038/cdd.2012.106)

[5. (Letellier2014Identification) E Letellier, M Schmitz, K Baig, N Beaume, C Schwartz, S Frasquilho, L Antunes, N Marcon, P V Nazarov, L Vallar, J Even, and S Haan. Identification of socs2 and socs6 as biomarkers in human colorectal cancer. British Journal of Cancer, 111(4):726–735, July 2014. URL: http://dx.doi.org/10.1038/bjc.2014.377, doi:10.1038/bjc.2014.377. This article has 49 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/bjc.2014.377)

[6. (Ouyang2021Downregulation) Jun Ouyang, Tailai An, Yan Wang, Xiaofang Lu, Yawei Zhang, Xiaokun Wang, Xinhua Zhang, and Changhua Zhang. Down-regulation of socs6: an unfavorable prognostic factor for gastrointestinal stromal tumor proven by survival analysis. Diagnostic Pathology, December 2021. URL: http://dx.doi.org/10.1186/s13000-021-01172-6, doi:10.1186/s13000-021-01172-6. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13000-021-01172-6)

[7. (Bayle2004Suppressor) Julie Bayle, Sébastien Letard, Ronald Frank, Patrice Dubreuil, and Paulo De Sepulveda. Suppressor of cytokine signaling 6 associates with kit and regulates kit receptor signaling. Journal of Biological Chemistry, 279(13):12249–12259, March 2004. URL: http://dx.doi.org/10.1074/jbc.M313381200, doi:10.1074/jbc.m313381200. This article has 99 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M313381200)

[8. (Sriram2012ArrayComparative) Krishna B. Sriram, Jill E. Larsen, Santiyagu M. Savarimuthu Francis, Casey M. Wright, Belinda E. Clarke, Edwina E. Duhig, Kevin M. Brown, Nicholas K. Hayward, Ian A. Yang, Rayleen V. Bowman, and Kwun M. Fong. Array-comparative genomic hybridization reveals loss of socs6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS ONE, 7(2):e30398, February 2012. URL: http://dx.doi.org/10.1371/journal.pone.0030398, doi:10.1371/journal.pone.0030398. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0030398)